Loading patent…
AssigneeEpigenomics AG
InventorsCatherine E Lofton-Day, Andrew Z. Sledziewski, Fabian Model, Susan Cottrell, Juergen Distler, Reimo Tetzner, Dimo Dietrich
Estimating the term…
The invention provides methods, nucleic acids and kits for detecting colorectal cell proliferative disorders based on underexpression or methylation of a least one gene selected from RASSF2, TFAP2E, SND1, PCDHGC3, EDNRB, STOM, GLI3, RXFP3, LimK1, GPR73L1, PCDH1O, DOCKIO and MRPS21, and optionally Septin-9. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said class of disorders, thereby enabling the improved diagnosis and treatment of patients.
A method for detecting a carcinoma in a subject comprising determining the expression levels of RASSF2 in a biological sample isolated from said subject wherein at least one of underexpression and CpG methylation is indicative of the presence of said disorder.
A method for detecting a cell proliferative disorder in a subject, comprising contacting genomic DNA isolated from a biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one target region of the genomic DNA, wherein the target region comprises, or hybridizes under stringent conditions to a sequence of at least 16 contiguous nucleotides of SEQ ID NO:1, wherein said contiguous nucleotides comprise at least one CpG dinucleotide sequence, and whereby detecting carcinoma is, at least in part, afforded.
A method for detecting cancer, comprising:
A treated nucleic acid for use in the detection of cancer derived from genomic SEQ ID NO:1 wherein the treatment is suitable to convert at least one unmethylated cytosine base of the genomic DNA sequence to uracil or another base that is detectably dissimilar to cytosine in terms of hybridization.
(canceled)
(canceled)
Dependencies are inferred from the claim text.